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Abstract 
Background/Introduction: Diabetes and cardiovascular disease develop in concert with metabolic abnormali-
ties mirroring and causing changes in the vasculature, particularly the microcirculation. The microcirculation can be 
affected in different parts of the body of which the skin is the most easily accessible tissue.
Purpose: The association between diabetes and dermal microvascular dysfunction has been investigated in obser-
vational studies. However, the strength of the association is unknown. Therefore we conducted a systematic review 
with meta-analysis on the association between diabetes and dermal microvascular dysfunction as assessed by laser 
Doppler/laser speckle contrast imaging with local thermal hyperaemia as non-invasive indicator of microvascular 
functionality.
Methods: PubMed and Ovid were  systematically searched for eligible studies through March 2015. During the first 
selection, studies were included if they were performed in humans and were related to diabetes or glucose metabo-
lism disorders and to dermal microcirculation. During the second step we selected studies based on the measure-
ment technique, measurement location (arm or leg) and the inclusion of a healthy control group. A random effects 
model was used with the standardised mean difference as outcome measure. Calculations and imputation of data 
were done according to the Cochrane Handbook.
Results: Of the 1445 studies found in the first search, thirteen cross-sectional studies were included in the meta-anal-
ysis, comprising a total of 857 subjects. Resting blood flow was similar between healthy control subjects and diabetes 
patients. In contrast, the microvascular response to local skin heating was reduced in diabetic patients compared to 
healthy control subjects [pooled effect of −0.78 standardised mean difference (95% CI −1.06, −0.51)]. This effect is 
considered large according to Cohen’s effect size definition. The variability in effect size was high (heterogeneity 69%, 
p < 0.0001). However, subgroup analysis revealed no difference between the type and duration of diabetes and other 
health related factors, indicating that diabetes per se causes the microvascular dysfunction.
Conclusion: Our meta-analysis shows that diabetes is associated with a large reduction of dermal microvascular 
function in diabetic patients. The local thermal hyperaemia methodology may become a valuable non-invasive tool 
for diagnosis and assessing progress of diabetes-related microvascular complications, but standardisation of the tech-
nique and quality of study conduct is urgently required.
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Background
Diabetes contributes to and accelerates cardiovascular 
disease [1, 2] and macrovascular complications, such 
as atherosclerosis [3], coronary artery disease [4, 5] and 
peripheral artery disease [6]. However, the most fre-
quently diagnosed complications in diabetic patients are 
related to the microcirculation, including foot ulcers [7], 
retinopathy [8], neuropathy [9], diabetic dermopathy 
[10] and diminished wound healing [11]. These diabetes-
related microvascular dysfunctions can eventually lead 
to more severe complications, illustrating the necessity 
to detect microvascular dysfunction in an early stage and 
identify diabetic patients at risk.
Diabetes may affect the microcirculation in different 
parts of the body from kidney to eyes and skin, but its 
function is most easily accessible in the latter. Moreover, 
skin microvascular function may already be affected in an 
early stage of the disease as has been assessed by invasive 
methodology [12].
Microvascular dysfunction used to be determined 
in feet and toes, as complications are first seen in these 
body parts. The microcirculation in feet and toes (simi-
lar to hands and fingers) can, however, fluctuate substan-
tially due to the presence of arteriovenous anastomoses 
[13, 14]. Tissue perfusion at these skin sites may therefore 
not be the most sensitive indicators of the severity and 
progress of the disease. The forearm and lower leg show a 
more stable microcirculation and measurements are less 
invasive. Therefore, the functionality of dermal microcir-
culation is nowadays more often measured in the fore-
arm and lower leg.
The most commonly used methods to measure micro-
circulation of the skin are laser Doppler flowmetry (LDF) 
[15] and laser speckle contrast imaging (LSCI) [16, 17]. 
These techniques measure the microvascular perfusion, 
are non-invasive, and provide a continuous measurement 
[17–20]. Surprisingly, resting dermal microvascular per-
fusion is apparently not affected in Diabetes, irrespective 
of the progress of the disease [21, 22]. The functionality 
of the microvessels may be a more sensitive indicator of 
complications, and different stimuli are used to deter-
mine microvascular response/reactivity [23]. Frequently 
iontophoresis is used in conjunction with LDF or LSCI. 
Although iontophoresis is generally considered as being 
safe, mild local allergic reactions and skin irritations have 
been observed in some subjects [24]. Another limitation 
of iontophoresis is that the drug delivery is influenced 
by skin resistance and this varies considerably between 
subjects and across different skin areas due to low-resist-
ance pathways in the skin such as sweat ducts or hair fol-
licles [24]. In addition, pH, ion competition in the buffer 
solution and biological factors such as age, gender, skin 
hydration and temperature can affect the drug delivery 
by iontophoresis and thereby contribute to the variation 
of the measured response. Moreover the iontophore-
sis procedure is rather time consuming and needs to be 
repeated at regular intervals [25]. An alternative is local 
skin heating, which is a stimulus that can be applied to 
induce local thermal hyperaemia (LTH) due to vasodila-
tion. As LTH is non-invasive, has a good reproducibility 
and allows to asses different mechanisms causing vaso-
dilation, LTH is one of the most commonly used patient-
friendly reactivity tests [20, 23, 26]. Already in the early 
90s, changes in dermal blood flow caused by diabetes 
have been measured with LDF in response to local heat-
ing [27]. In the “Methods” section both techniques are 
described in more details.
The association between diabetes mellitus and micro-
vascular dysfunction as measured by LDF/LSCI with 
LTH has been investigated in observational studies. 
However, the strength of the association is unknown. 
Therefore the aim of this study was to review the strength 
of the association between diabetes and dermal micro-
vascular dysfunction assessed by LDF/LSCI with LTH. 
Furthermore the difference in dermal microvascular 
function between T1DM patients and T2DM patients 
was assessed.
Methods
Selected measurement technique for dermal blood flow
LDF and LSCI are based on the same principle: laser light 
is directed towards target tissue, usually the skin. Light 
is scattered back on red blood cells and is then collected 
and analysed by optical probes [18]. The outcome is pre-
sented as blood flow or flux in arbitrary perfusion units, 
which are proportional to the microvascular perfusion 
but do not represent actual perfusion values. Neverthe-
less, these methods have a high sensitivity for the detec-
tion of relative changes in blood flow, are well validated, 
and are particularly used to determine change in perfu-
sion induced by a stimulus at different sites of the skin 
[16–18, 20, 28, 29]. As shortly described in the intro-
duction, LTH is caused by vasodilation due to local skin 
heating. The rise in local skin perfusion due to the vaso-
dilation is directly proportional to the skin temperature 
and reaches its maximum when a local skin temperature 
Keywords: Skin perfusion, Microcirculation, Vasodilation, Morphology, Laser Doppler flowmetry, Laser speckle 
contrast imaging
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of 44 °C is kept for at least 20 min and up to 50 min [23, 
30]. The LTH response shows two perfusion peaks which 
are mediated by independent mechanisms: (1) the initial 
peak during the first 10 min depends predominantly on 
local sensory nerves and is mediated by an axon reflex 
relying on calcitonin-gene-related peptide and substance 
P, (2) the plateau reached after 20–30  min of heating is 
primarily mediated by nitric oxide [20, 30–32].
Iontophoresis is a technique in which vasoactive sub-
stances are transdermally applied. The underlying prin-
ciple is the transfer of charged vasoactive drugs using a 
low-intensity electric current. Several drugs can be used 
for iontophoresis such as bradykinin, methacholine, and 
substance P. However, most frequently used drugs are 
acetylcholine (ACh) and sodium nitroprusside (SNP), 
which generate an endothelium-dependent and -inde-
pendent vasodilatation, respectively [23].
In this review, we have focussed on the LTH-skin 
response in diabetic patients, representing a relatively 
popular technique, and offering a patient-friendly alter-
native to most other procedures to assess microvascular 
dysfunction. Iontophoresis will be discussed to put the 
result of the meta-analysis into perspective.
Search strategy
The search strategy was developed and designed by PPD, 
DF and RD. A systematic search of the databases PubMed 
and Ovid was conducted including studies up to the 12th 
March 2015. All possible terms for skin, microcirculation, 
and glucose metabolism disorders were used as search 
terms in order to identify all possibly relevant studies. 
Search terms that were related to the exposure were: skin, 
dermal, dermis, cutaneous, nailfold, microcirc*, endothel*, 
microvasc*, microvascular function, iontophoresis, ace-
tylcholine, Ach, sodium nitroprusside, SNP, L-NMMA, 
local thermal hyper*, heat*, blood flow, perfusion, capil-
lary, vasodilation, laser Doppler, videocapillaroscopy, laser 
speckle, and Doppler. Search terms in relation to diabetes 
mellitus were: diabetes, diabetic, DM, insulin and glucose, 
insulin resistan*, pre-diabet*, HOMA, HbA1c, insulin sen-
sitiv*, hyperglyc*, OGTT, oral glucose tolerance test, glu-
cose challenge, and glucose load. Additionally, the search 
string contained the terms: human, adults, adolescents, 
subjects, participants, and volunteers. The search was fil-
tered on human studies, articles written in English, and 
search terms mentioned in the title or abstract.
Study selection
A two-step approach was followed to identify eligible 
studies. Both observational- and experimental-studies 
were deemed eligible, whereas only baseline results were 
used from experimental studies if included. The flowchart 
of the selection procedure is depicted in Fig. 1. First, two 
reviewers (PPD and RD) independently screened title 
and abstract of all retrieved studies (n =  1445) to iden-
tify potentially eligible studies. In a second step, full-texts 
of the studies were scrutinized by PPD and DF indepen-
dently to judge eligibility based on the following selection 
criteria: (1) Laser Doppler flowmeter or LSCI were used 
to measure microcirculation of the skin, (2) LTH was 
used as stimulus, (3) measurements were done on arm or 
leg (not hands, feet, fingers, or toes), (4) studies had both 
a diabetes group and a (healthy) matched control group, 
(5) studies were not conducted in patients with any rel-
evant concomitant disease (e.g. no heart failure, dialysis 
patients). When inconclusive, eligibility was discussed 
(PPD, RD and DF) until consensus was reached. When 
relevant results (e.g. mean values, duration of heating) 
were missing or incomplete, the authors of these stud-
ies were contacted to obtain the missing information. If 
authors did not respond, the study was excluded from the 
meta-analysis.
Data extraction and meta‑analysis
Baseline characteristics and population details were 
extracted from all included studies: type of diabetes, 
methodology to determine diabetes, population size, 
gender distribution in both diabetes—and control group, 
age distribution, and BMI. Secondly, information regard-
ing methodology was extracted to identify differences 
in studies: type of study, specific type of laser Doppler 
used, duration and temperature of heat stimulus, and 
location(s) of measurement.
Results were presented in different outcome units 
by the included studies. Blood flow was presented in 
arbitrary perfusion units (PU), flux, milliliter  ×  min-
ute−1 × 100 g of tissue−1, and Volts (1PU is a pre-defined 
electrical signal in mV). As the blood flow was presented 
in different units, the results were calculated into stand-
ardised mean differences [33]:
Mean values and standard deviations of basal flow 
and peak flow were used to calculate the standardised 
mean difference for the response to LTH as measured 
with laser Doppler/LSCI between diabetic patients and 
healthy control subjects [34]. The SMD is an outcome 
measure that is difficult to interpret as it does not give an 
absolute difference or ratio. Cohen designed an effect size 
index to interpret the importance of the found effect [35]. 
According to Cohen, an effect size of 0.2 SMD is consid-
ered small, 0.5 SMD medium, and 0.8 SMD large.
The meta-analysis was performed in Review Manager 
5.3. The I2 was determined to check for heterogeneity 
Standardised mean difference
=
Increase in diabetes group− Increase in control group
Pooled standard deviation
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between studies [36]. If the I2 was 50% or higher, it was 
assumed there was substantial heterogeneity [37]. If 
heterogeneity was assumed, subgroup analysis was per-
formed. A random effects model was used in case hetero-
geneity was not explained by the subgroup analysis.
When the standard deviations of the absolute changes 
from baseline were not available from individual stud-
ies, the missing standard deviations were imputed as 
described in detail in the Cochrane Handbook [38–40]. 
The correlation coefficients were calculated from an 
unpublished validation study performed by Unilever 
R&D Vlaardingen presenting standard deviations for 
basal flow (77.6 AU), peak flow (peak 1: 210.1 AU; pla-
teau: 238.4 AU), and change (peak 1 vs baseline: 148.2 
AU; plateau vs baseline: 201.0 AU). By using these 
imputed correlation coefficients, the standard deviations 
of the change from basal flow to peak flow were calcu-
lated for the studies missing the standard deviations.
Several studies contained multiple diabetes groups, e.g. 
a non-neuropathic diabetes group and a neuropathic dia-
betes group. These groups were analysed as if they were 
separate studies. The shared control group, the healthy 
control subjects, was evenly divided among the two dia-
betes groups and used as two separate control groups as 
described in the Cochrane Handbook [38]. The outcome 
is continuous, therefore the mean change was the same in 
both control groups.
A priori variables were determined that could have 
an effect on the outcome. These variables were used to 
define subgroup analyses. Regarding participant char-
acteristics age (young to old), type of diabetes (type 1 
vs type 2), BMI (normal weight to obesity), duration of 
diabetes (short duration to long duration), and glycated 
haemoglobin (low HbA1c value to high HbA1c value) were 
determined as possible influential variables. Regarding 
methodology the duration of the heat stimulus (<20 min 
vs  >20  min) and location of measurement (forearm 
vs tibia vs quadriceps) were deemed to be of possible 
influence.
Eligible studies were also evaluated on quality of con-
duct and/or reporting. For the quality assessment we 
used a list of quality criteria that was developed by 
Downs and Black to assess the quality of observational 
studies [41]. The criteria were adapted for use for our 
analysis, involving only studies without medical inter-
vention (Additional file  1). The highest possible quality 





The systematic search yielded a total of 1445 studies. 
During the first selection, studies were excluded that 
did not meet the criteria (Fig.  1), resulting in the selec-
tion of 314 studies. After the second selection procedure, 
22 studies were selected as eligible for inclusion in the 
meta-analysis. The reference lists of these 22 studies were 
Fig. 1 Flowchart of study selection
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searched for eligible studies, which yielded one addi-
tional study. Finally, a number of the eligible studies were 
excluded from the meta-analysis due to crucial missing 
results or incorrect methods. Another reason of exclu-
sion was that LTH was not the only stimulus and that 
therefore the effects of LTH could not be separated from 
other stimuli. This resulted in the inclusion of 13 studies 
in the meta-analysis.
Overview of included studies
All 13 included studies were analytical cross-sectional 
studies, investigating the association between a risk fac-
tor and outcome at a single point in time. These studies 
contained a total of 857 participants with the number 
of participants in each study ranging from 20 to 150 
(Table 1).
All studies used a laser Doppler flowmeter. Basal flow 
was standardised to a normal temperature. These tem-
peratures ranged from 30 to 35  °C. The temperature to 
obtain maximum vasodilation was 44 °C in most studies. 
Only two studies used a lower temperature, i.e. 43 °C [42] 
and 42  °C [43]. The included studies differed on several 
methodological characteristics. Duration of the heat-
ing to obtain maximum vasodilation: in five studies the 
skin was heated for less than 20  min [42, 44–47], while 
in eight studies heating was applied for 20 min or more 
[43, 48–54]. There were three locations of measurements: 
eight studies measured on the forearm [42, 43, 46–48, 
52–54], three on the pretibial surface of the leg [49–51], 
and two on the quadriceps muscle [44, 45].
Pooled overall risk estimate
Baseline dermal blood flow did not differ between con-
trol and diabetes group (p  =  0.51). The pooled overall 
estimate showed a lower microvascular response to local 
thermal stimulus of −0.78 SMD (95% CI −1.06, −0.51) 
in diabetic patients compared to control subjects (Fig. 2). 
The mean estimates of all studies showed a lower SMD 
in the diabetic patients compared to the control group of 
which eleven subgroups out of ten studies reached signif-
icance [43–45, 47, 48, 50–54].
Heterogeneity analysis
A heterogeneity of 69% (p  <  0.0001) was found in the 
meta-analysis. Therefore heterogeneity was assumed and 
subgroup analyses were performed. However, the latter 
could not explain the heterogeneity and a random effects 
model was used.
Fig. 2 Forest plot of pooled overall effect of microvascular function in diabetic patients versus control subjects based on a random effects model. 
Studies containing subgroups (for instance Arora 1998a and Arora 1998b) were studies presenting two different diabetes groups. The a-subgroups 
contained diabetic patients with additional complications and the b-subgroups diabetic patients without complications
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Subgroup analyses
A priori, several variables were selected to be of possible 
influence on the effect. There were no differences between 
studies conducted on T1DM, T2DM, or both types of 
diabetes. The studies that did not specify the type of dia-
betes [44, 45] were significantly different, with an SMD 
of −2.52 (95% CI −3.40, −1.64, I2 0%) (Fig. 3). However, 
this difference may also be explained by the unique loca-
tion of the measurement [44, 45]. Only in these studies 
blood flow was determined on the quadriceps and showed 
a significant different effect size compared to studies 
conducted on the forearm (−0.71 SMD, 95% CI −1.01, 
−0.41) or pretibial surface (−0.58 SMD, 95% CI −0.99, 
−0.16) (Fig.  4). Subgroup analyses for the variables age, 
BMI, duration of diabetes, HbA1c, and duration of heating 
showed no significant effects (data not shown).
Quality of conduct of the eligible studies was moderate 
(10 studies scored 6–11 out of 17; Table 1).
Evidence from systematic literature review
Iontophoresis
The first selection of studies (n  =  314) was checked 
for studies eligible for a systematic review of the 
microvascular reactivity after iontophoresis with ACh 
and SNP. Based on the criteria mentioned in the “Meth-
ods” section  22 studies were suitable for inclusion. 6 of 
the 22 studies did not make a distinction in the types of 
diabetes [54–59], 6 were conducted in T1DM [52, 53, 
60–63] and 11 in T2DM patients [12, 43, 63–70].
Several studies not differentiating between types of dia-
betes showed a diminished response to ACh [54, 55, 57, 
59] and SNP [54, 55, 57] iontophoresis in diabetic patients. 
However, the differences seem to be more marked and 
more significant after ACh iontophoresis than after SNP 
iontophoresis [55, 57]. Studies comparing T1DM patients 
with healthy controls show similar results. The reduction 
in blood flow due to diabetes seems to be clearer after ion-
tophoresis with ACh than after iontophoresis with SNP 
[52, 53, 61]. Next to a reduction in peak vasodilation, Katz 
et al. [60] showed that time to peak vasodilation after ACh 
iontophoresis was doubled in diabetic subjects compared 
to controls, while there was no difference after SNP ionto-
phoresis. Three studies reported a difference in response 
to both ACh and SNP between patients with T2DM and 
control subjects [12, 43, 64]. The differences were similar 
in all three studies and microvascular response was shown 
Fig. 3 Forest plot of subgroup analysis for microvascular function according to type of diabetes
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to be reduced by a third for both vasoactive substances. 
A study [63] comparing the microvascular reactivity of 
patients with T1DM, T2DM, and healthy control subjects, 
observed a reduced response to ACh in subjects with 
T2DM, but did not report a difference in response to SNP. 
In contrast, two studies reported a significant difference 
between patients with T2DM and control subjects for 
SNP iontophoresis but not for ACh iontophoresis [68, 69]. 
The response to SNP iontophoresis was reduced by a third 
in diabetic patients compared to control subjects. Three 
studies, however, observed no differences between T2DM 
patients and healthy control subjects [65–67]. Caballero 
et al. [12] described a reduced response, assessed as peak 
vasodilation and percentage increase over baseline, to 
ACh and SNP in patients with impaired glucose tolerance 
and relatives of diabetic patients as compared to healthy 
control subjects. Although not significant, the response 
gradually decreased from relatives of diabetic patients 
to subjects with impaired glucose tolerance to diabetic 
patients [12]. Two of three studies with diabetic patients 
with microvascular complications (albuminuria, neuropa-
thy or retinopathy) observed at least a trend towards an 
additional impairment in microvascular function as com-
pared to diabetic patients without complications [54, 69].
Discussion
The present meta-analysis provides a number of impor-
tant observations. First, our meta-analyses shows an 
effect size of the association between diabetes mel-
litus and microvascular dysfunction as assessed by 
LTH response that can be considered to be nearly large 
according to Cohen’s effect size index [35]. Secondly, sub-
group analysis showed a difference in effect size between 
locations of measurement. The fact that the response 
reported in studies conducted in the quadriceps muscle 
was more reduced than in the forearm or pretibial surface 
could suggest that assessment of dermal microvascular 
function at the quadriceps would be the preferred choice 
to discriminate healthy from diabetic subjects. However, 
these findings are limited by the small subgroup size for 
the quadriceps (n  =  40) and being conducted by only 
one research group [44, 45]. The relatively small stand-
ard deviation reported by this group affects the SMD size 
effect [44, 45] and could either represent the excellence 
of measurement or a typical smaller variation specifically 
for the quadriceps as measurement site.
Thirdly, no differences in effect size were found 
between T1DM and T2DM or whether both types of 
diabetes were included, which may indicate that the 
Fig. 4 Forest plot of subgroup analysis for microvascular function according to location of measurement
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microvascular function is impaired by diabetes per se 
and not by a factor common to either T1DM or T2DM. 
Patients with T1DM tend to be younger, leaner, have had 
diabetes for a longer period and a worse glycemic control 
compared to T2DM patients [71] and thus could have a 
poorer microvascular health. However, T2DM patients 
tend to be overweight and are older in age [71], char-
acteristics that could also impair the microcirculation. 
Our observation is confirmed by the fact that sensitivity 
analyses for age, BMI, duration of diabetes, and HbA1c 
revealed no explanation for the heterogeneity of the data.
Likewise, no differences were found in subgroup analysis 
for duration of heating. However, the comparison is lim-
ited since the data was not reported optimally in a num-
ber of studies. The heating procedure should at least take 
40 min to allow detection of the nerve-axon reflex-related 
first peak within the first 10  min, followed by a nitric 
oxide-dependent plateau-phase at the end of the proce-
dure [72]. In a number of studies the plateau-phase was 
likely not reached yet. These issues give possible explana-
tions for the lack in differences in subgroup-analyses.
It is interesting to note that four studies included two 
different diabetes groups: a group of diabetic patients 
with additional microvascular complications such as 
dermopathy and a group of matched diabetic patients 
without these complications [47, 49, 51, 54]. Although 
not considered a priori, these studies allowed us to differ-
entiate between diabetic patients with and without addi-
tional microvascular complications. The findings of these 
studies indicate that the diabetes group with additional 
complications had an attenuated response compared to 
the groups without these complications. Even though the 
observed difference between these groups was not sig-
nificant, the attenuated response in diabetic patients with 
additional complications may support our hypothesis 
that a longer duration of diabetes and additional compli-
cations in diabetic patients are associated with a larger 
degree of impairment of the microvascular reactivity. In 
line with our assumption, other groups reported an addi-
tional worsening of microvascular function in diabetic 
patients with microvascular complications [73–75].
As LTH causes vasodilation by different mechanisms, 
a nerve-axon reflex and a nitric oxide-mediated peak 
[72], this reactivity test was deemed to successfully assess 
which aspect is impaired in diabetes. However, due to the 
lack of guidelines on reactivity tests with a heat stimulus, 
studies differed in duration of heating. Therefore the dif-
ference between the two peaks could not be assessed and 
the underlying mechanism resulting in microvascular 
dysfunction in diabetes could not be reviewed. Overall, 
consensus on standardisation of the microvascular LTH 
response is required to qualify the method as a patient-
friendly diagnostic tool.
The quality of study conduct was moderate. This may 
reflect either the quality of the study design, but may also 
be affected by (poor) description and reporting of the 
study. Therefore, the quality assessment was not used for 
excluding studies. The quality assessment has revealed 
that the conduct (or reporting thereof ) of dermal micro-
vascular function as assessed by the LTH response in 
diabetic patients requires improvement. This conclusion 
supports the recommendation to strive for standardiza-
tion of the methodology.
Multiple studies reported a reduction in vasodilation in 
diabetic patients after iontophoresis of particularly ACh 
[52, 53, 55, 57, 61–63]. This implies that the microvascu-
lar dysfunction in diabetic patients is essentially endothe-
lium-dependent. Also, the impairment appears to be 
more evident in type 1 diabetes than in type 2 diabetes. 
This may be due to the longer duration of diabetes in 
type 1 diabetic patients and the worse glycaemic control, 
which may enhance the microvascular impairment, as an 
increase in HbA1c values was found to be correlated with 
a decrease in microvascular response [43, 47, 64, 76, 77]. 
This correlation is in line with the observation by Cabal-
lero et  al. [12] that microvascular reactivity gradually 
decreased from relatives of diabetic patients to subjects 
with impaired glucose tolerance to diabetic patients. In 
addition, two studies with diabetic patients with micro-
vascular complications reported at least a trend towards 
an additional impairment in microvascular function as 
compared to diabetic patients without complications 
[54, 69]. However, those effects were not significant and 
the evidence for a stepwise impairment of microvascu-
lar function from subjects at risk for diabetes to diabetic 
patients with complications is rather limited.
Strengths and limitations
This review has several strengths. It is the first system-
atic review on dermal microvascular dysfunction in dia-
betes and provides a clear insight in this association. 
Many studies have been conducted addressing this topic, 
but general consensus was not created yet. Furthermore, 
we used the PRISMA Statement [78] and the Cochrane 
Handbook [37] as guidance for this systematic review. 
This ensures a clear structure of our review and objective 
methods for data-extraction and -analysis.
Nevertheless, our meta-analysis also has several limita-
tions. Importantly, we observed heterogeneity between 
studies. Meta-analyses include studies with differences 
in study design and additionally are prone to be affected 
by confounding. The number of subjects (n  =  857) 
included was limited, whilst the variance between stud-
ies in characteristics of the participants and methodol-
ogy used may have been too large to reveal the major 
contributors to the heterogeneity. Laser Doppler and 
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LSCI in combination with local thermal hyperaemia are 
frequently used methods. Nevertheless, there are no offi-
cial guidelines available for these measurements and a 
better standardization is required [73]. Cracowski et  al. 
[20] developed ten suggestions which should be followed 
to minimize the variability of these measurements. The 
lack of official guidelines explains why studies differed on 
methodological aspects such as location of measurement, 
duration of heating, maximum temperature or outcome 
measure. The development and implementation of offi-
cial guidelines for laser Doppler measurements in com-
bination with LTH would improve the reproducibility of 
the measurement and the comparability of data between 
studies.
Another limitation was the difference in outcome meas-
ures between studies. Not only the unit was different, the 
absolute values of these outcome measures were also dif-
ferent in range and for this reason we used the SMD. SMD 
provides an indication of the strength of the association 
between diabetes and dermal microvascular dysfunction, 
but cannot be used to determine the absolute difference 
between diabetic patients and control subjects.
Furthermore, the quality of reporting of the selected 
studies was not optimal. For example, the gender of the 
subjects or use of medication is not reported in all publi-
cations. This is reflected in the scores the studies received 
during the quality assessment. Moreover, ten eligible 
studies were excluded from the analysis due to missing 
data and no response from the authors, or due to the 
use of an additional stimulus besides local heating. The 
excluded studies showed similar results as the included 
studies and therefore it is unlikely that the exclusion of 
these studies substantially influenced the findings.
Conclusions
Diabetic patients show an impaired dermal microvascu-
lar hyperaemic response to local heating compared to 
healthy subjects. An important issue for future research 
is the implementation of guidelines for microvascular 
LTH response to strengthen the validity of this tool for 
assessing (progress of ) diabetes-related microvascu-
lar complications. Further LDF/LSCI studies including 
higher number of healthy subjects, prediabetic subjects 
and diabetic patients with and without complications 
would be required to demonstrate the stepwise impair-
ment of microvascular function in diabetes and to con-
firm the applicability of LDF/LSCI as a diagnostic tool.
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